|
Re: Enhertu
My wife has been on Enhertu since May/2022. During the first 7 months her CA27.29 dropped very fast, but the last 3 Ca27.29 has been rising, we'll have scans next month to check status. Her Ca27.29 has been correlated 100% with imaging for the last 20+ years.
She has been on continuous treatment with trastuzumab (herceptin) or trastuzumab based (T-dm1, T-DxD, etc) regimens all these years. Her left ventricle ejection fraction (LVEF) and left ventricular global longitudinal strain (LV-GLS) had been in normal range. But they have just dropped out of normal range with this month echo cardiogram. Heart damage is a risk factor from Herceptin based regimens, since there are her2 receptors in the heart's cells and elsewhere. With the well known by-standers effect of T-Dxd (Enhertu), it affects the heart more. I hope you have echo cardiogram regularly.
Nguyen
|